Therapy Area topics
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Central Nervous System
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
Aduhelm’s likely EU rejection comes amid a key senior executive departure and federal inquiry, and the drug now faces a crucial Medicare decision.
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
A bad situation gets worse – again – and rivals seek to capitalise.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.